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Summary Immunocytochemical staining with monoclonal antibody NCRC 11 of formalin fixed paraffin
embedded tumour tissue has been studied in 444 cases of primary breast cancer with a minimum follow
period of 6 years. The relationship between extent of staining, assessed on a four point scale, and patient
survival has been confirmed. There are significant relationships between staining and both histological grade
and oestrogen receptor status. No association has been shown between staining and lymph node stage or
tumour size. Simplification of staining assessment by modification to two staining groups still allows
significant separation of patients into prognostic groups and incorporation into an existing prognostic index.
NCRC 11 is a mouse monoclonal antibody which was raised
against human breast carcinoma cells (Ellis-et al., 1984). The
immunoreactivity of this antibody in normal tissues has been
described and is similar to other monoclonal antibodies
raised against human milk fat globule membrane (HMFGM)
(Ellis et al., 1984). Using these antibodies some workers have
shown a relationship between immunocytochemical staining
and patient survival (Wilkinson et al., 1984) but others have
failed to show any prognostic significance (Berry et al.,
1985; Rasmussen et al., 1985). A preliminary study using
NCRC 11 showed a relationship between immunocyto-
chemical staining of formalin fixed paraffin embedded
tumour tissue sections and patient survival (Ellis et al.,
1985). We now report a further large retrospective study of
primary breast cancer patients using this antibody.
Materials and methods
Clinical data
Five hundred consecutive patients presenting to one surgeon
(RWBI) with primary operable breast cancer were selected
for study. The patients presented between 1973 and 1979 and
have a minimum follow up period of 6 years. Patients were
excluded because of lack of follow up information, if in situ
tumour only was present, or if insufficient tumour tissue
remained for study. This left 444 cases in the study group.
All the patients were treated by simple mastectomy with
node sampling from the low axilla, the apex of the axilla,
and the internal mammary chain at the second intercostal
space. All were followed up at 3 monthly intervals to 18
months, then every 6 months to 5 years, and once a year
thereafter. No prophylactic radiotherapy was given. A small
group of women were given adjuvant chemotherapy, but this
failed to influence survival (Haybittle et al., 1982).
Detailed clinical and pathological information was avail-
able on all patients, including histological grade and lymph
node stage. Histological grade was assessed by a modifi-
cation of the method of Bloom and Richardson (1957)
described by Elston (1984). In 389 cases oestrogen receptor
status was determined by the dextran coated charcoal
method (Maynard et al., 1978). Tumours were considered to
be positive for oestrogen receptor if values greater than
5 fmol mg- 1 cytosol protein were found.
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Immunohistology
On resection, the tumours were received in the operating
theatre anteroom, incised in the fresh state and fixed in
phosphate buffered formalin for 24h. Tissue blocks were
processed routinely for histopathological examination and
embedded in paraffin wax. From each case one representa-
tative block was selected and tissue sections 4,um thick were
cut. The immunocytochemical method selected, because of
its high sensitivity, was a 4 stage peroxidase antiperoxidase
technique (Sternberger, 1979). Diaminobenzidine was used
as the chromogen and the sections were counterstained with
haematoxylin.
NCRC 11 was applied as cell culture supernatant fluid. To
standardise the methodology as much as possible a single
batch, with a concentration of 10 ugml-1, was used through-
out the study. The intermediate step reagents and their
dilutions were: rabbit antimouse immunoglobulin, I in 100
(Dako no. Z259); swine antirabbit I in 40 (Dako no. Z196);
rabbit peroxidase antiperoxidase complex I in 200 (Dako no.
Z113).
In our preliminary study (Ellis et al., 1985) we used similar
commercial antisera which were in routine use in our
laboratory. In subsequent unpublished work we noticed a
greater degree of staining in a series of breast cancers under
study. This observation followed replacement of some of the
intermediate step antibodies by the manufacturer for
improved antibodies. These, especially the rabbit antimouse,
appear to be of higher affinity and have increased the
sensitivity of the peroxidase antiperoxidase technique
allowing detection of low levels of antigen which were
undetectable previously.
Reduction of the NCRC 11 concentration below a titre of
1 in 10 reduced the proportion of cells detected as positive in
some cases. The cells which lost detectable staining had a
light diffuse cytoplasmic staining pattern when observed as
positive. Increase of the NCRC 11 concentration, using a
purified antibody preparation, did not increase the pro-
portion of cells detected as positive in the cases studied.
Similarly trials of two other sensitive immunocytochemical
techniques, the immunogold silver staining method (Holgate
et al., 1983) and the avidin biotin complex system (Hsu et
al., 1981), did not increase the proportion of cells staining
positively.
In each case a negative control section was stained using a
mouse IgM monoclonal antibody against sheep erythrocytes
(Sera-Lab). A positive control section of breast carcinoma of
known reactivity was included with each batch to ensure
consistency.
C The Macmillan Press Ltd., 1987 Br. J. Cancer (1987), 56, 295-299296 I.O. ELLIS et al.
Scoring ofstaining
The staining of each tumour was assessed in a semi-
quantitative manner by two observers (IOE, JB) synchronously
using a double headed microscope, without prior knowledge
of the clinical or pathological data. Each slide was scanned
at low power magnification ( x 63) and selected areas at high
power magnification (x 160 and x 400). The number of
tumour cells staining positively was assessed and scored on
a four point scale based on the proportion of the total
number of tumour cells: 1-25% = 1, 26-50% =2, 51-75% =3,
76-100% =4. A cell was counted as positive if stain product
was present on all or part of the cell surface membrane or in
the cytoplasm. In this study no account was taken of the
intensity of stain product nor of the difference in staining
patterns (surface or cytoplasmic) of the tumour cells.
To test reproducibility 44 cases were selected using
random number tables, restained and scored.
Results
Of the 444 cases studied only one showed no evidence of
staining. This was an unusual case of spindle cell carcinoma
type. There was a variation of staining observed in the 443
positive cases, from cases with all tumour cells staining
positively to cases with less than 10 cells positive in the
entire tissue section (Figure 1). They were distributed
Figure 1 Five cases of invasive adenocarcinoma of breast showing the range of immunohistological staining with NCRC 11 from
over 75% of tumour cells positive, group 4 (a, predominantly luminal surface staining and b, predominantly cytoplasmic staining);
50-74%, group 3 (c); 25-49%, group 2 (d); to 1-25%, group 1 (e) ( x 220).
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between the grades as follows:
1: 48 (11%), 2: 48 (11%), 3: 109 (25%), 4: 238 (53%).
Of the 44 cases restained 34 (78%) were scored identically
the remainder were placed in an adjacent staining group.
The relationship between staining and histological grade
oestrogen receptor status, lymph node stage and tumour size
are shown in Tables I, II, III and IV respectively.
Table I NCRC 11 staining versus histological grade
NCRC 11 staining
1 2 3 4 Total
Histological I 5 1 17 48 71
grade II 10 15 38 85 148
III 33 32 54 95 214
Total 48 48 109 228 433
x2=22.67 (6df) P<0.001.
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Survival curves for patients according to NCRC 11
Table II NCRC 11 staining
receptor status
versus oestrogen
NCRC 11 staining
1 2 3 4 Total
ER +ve 22 23 43 74 162
ER-ve 17 18 48 144 227
Total 39 41 91 218 389
x2= 13.52 (3df) P<0.01.
Table III NCRC 11 staining versus lymph node
stage
NCRC 11 staining
1 2 3 4 Total
Lymph node stage
A 25 28 63 127 243
B 12 15 28 75 130
C 11 5 18 36 70
Total 48 48 109 238 443
X2=3.69 (6df). Not significant.
Table IV NCRC 11 staining versus tumour size
NCRC 11 staining
1 2 3 4 Total
Tumour size
<2cm 15 20 47 92 174
2-5cm 24 24 43 123 214
>5cm 9 4 18 23 54
Total 48 48 108 238 442
x2=8.88 (6df). Not significant.
Survival curves for the patients grouped according to
staining of their tumours with NCRC are shown in Figure
2. These results show, a significant relationship between
NCRC staining and survival. Patients whose tumours
show a high proportion of positive staining cells have a
better survival compared to those patients whose tumours
have low numbers of positive cells.
Combination of staining groups would help simplification
of the scoring method. Figure 3 shows the survival curves of
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Figure 3 Survival curves for patients of staining groups 3 and 4
combined and 1 and 2 combined.
groups 3 and 4 combined (>50% cells stained) and groups 1
and 2 combined (<50% cells stained).
Simplification of staining assessment in this manner allows
incorporation of NCRC 11 staining into an existing
prognostic index for primary breast cancer. This prognostic
index uses a combination of values for lymph node stage,
histological grade and tumour size, in the formula
PI=0.2 x size + stage + grade, and has been shown to be a
highly accurate method of predicting prognosis in patients
with breast cancer (Haybittle et al., 1982). This index has
been applied to the study group using the cut off points of
<3.4 and >5.4 identified previously (Haybittle et al., 1982).
Three groups of patients with a good (<3.4), moderate (3.5-
5.3) and a poor (>5.4) survival are identified (Figure 4).
Subdivision of each group based on NCRC 11 staining grade
(Figure 5) identifies a significant bad prognostic subgroup in
the good and poor prognostic groups.
To test whether this relationship of NCRC 11 staining
with survival was independent of other prognostic factors a
Cox analysis (Cox, 1972) was performed. The Cox method is
a multiple regression technique which allows a variable to be
evaluated independently whilst taking into account the
effects of other variables. The analysis generates a value (fi)
that relates the contribution of the factor to the hazard (in
this case death). A positive value for indicates that higher
values of the factor are associated with higher risk. A
negative value for # indicates that higher values of the factor
are associated with lower risk. To test the significance of,
the ratio of its absolute value to its standard error is
,4
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2for trend = 19.6 on 1 df
p <0.001
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Figure 4 Survival curves of the prognostic groups identified in
the study group using the Nottingham Prognostic Index
(G =good prognostic group, moderate prognostic group and
P=poor prognostic group. See the text for details of the
formula.)
calculated (Z). Values of Z greater than 1.96 are significant
at the 5% level.
We examined the relationships of NCRC 11 staining,
histological grade, age, menopausal status, oestrogen
receptor status, lymph node stage and tumour size to
survival. The results of this Cox analysis (Table V) indicate
that the relationship between NCRC 11 staining and survival
is significant when analysed in conjunction with these other
prognostic factors. In the group of patients studied, histo-
logical grade, lymph node stage and NCRC 11 staining are
the only factors of significant value.
Table V The results of the Cox multiple regression
analysis
Z f
Patient age -0.35 -0.004
Menopausal status -0.22 0.055
Tumour size 1.67 0.088
Histological grade 4.85a 0.583
Lymph node stage 7.65a 0.719
Oestrogen receptor status -1.16 -0.175
NCRC 11 staining -3.07a _0.207
aValue > 1.96 is significant.
Discussion
In patients with primary operable breast cancer histological
grade and the presence of lymph node metastases at the time
of mastectomy are recognised as the most important pre-
dictors of prognosis (Haybittle et al., 1982). The current
trend towards conservative breast surgery reduces the tissue
available for sampling. Unless formal lymph node biopsy is
carried out nodal tissue for staging will not be available. All
possible information related to patient outcome available
from the primary tumour will be of use in management of
that patient. At present if the lymph node stage is not
known then the histological grade is the most reliable
predictor of survival. Antigen expression is one area of
exploration for potential prognostic factors. In a previous
preliminary study we showed a clear relationship between
the immunoreactivity of primary breast cancers with
antibody NCRC11 and the clinical course of the disease
(Ellis et al., 1985). This relationship has been confirmed, and
the results when entered in a Cox multiple regression
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Figure 5 Survival curves showing the separation of each
prognostic group by addition of NCRC 11 staining. (A) Good
prognostic group+NCRC 11; (B) moderate prognostic
group+NCRC 11; (C) poor prognostic group+NCRC 11.
analysis are shown to be of significant value along with
histological grade and lymph node stage.
Histological grade and oestrogen receptor status show a
strong direct relationship (Williams et al., 1984), and both
have an association with NCRC 11 staining. It is probable
that production of NCRC 11 antigen is related to tumour
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cell differentiation and the associations with histological
grade and ER would be expected. Both lymph node stage
and tumour size are factors related to time and show no
relationship to NCRC 11 staining.
Simplification of the scoring technique by combining
groups 1 and 2, and groups 3 and 4 also gives significant
patient stratification. This should reduce intra and inter
observer error and make assessment of staining more
applicable to routine use. A prognostic index using histo-
logical grade, lymph node stage and tumour size has been
shown to be an accurate predictor of patient outcome in
breast carcinoma (Haybittle et al., 1982). The results of this
study indicate that addition of NCRC 11 staining grade can
improve this prognostic index by identification of bad
prognostic subgroups in the good and poor prognostic
groups. It may be possible to improve the prognostic index
further by incorporation of NCRC 11 staining with, or as a
substitute for tumour size.
The distribution between the staining groups is different
from the results of our previous published preliminary study
(Ellis et al., 1985) where 27% of cases were scored as
staining group 1 (1-25% cells positive), 28% staining group
2, 35% staining group 3, and 10% staining group 4. Since
carrying out that work there has been a general
improvement of immunocytochemical reagents available
commercially and the sensitivity of techniques used in most
laboratories has improved accordingly. We believe this to be
the explanation for the differences in staining seen in the two
series. That is, with increase in sensitivity of the immuno-
histological method a proportion of cases with low cellular,
predominantly intracytoplasmic, antigen levels are now
identified as positive. Increasing the titre of NCRC 11 and
trials of other sensitive immunocytochemical techniques did
not increase further the proportion of cells detected as
positive. Recognition of these cells as positive has resulted in
this change in distribution, with over 50% of cases having a
high proportion of tumour cells staining positively. Despite
this change in sensitivity of the immunocytochemical
method, the relationship between NCRC 11 staining and
patient survival persists.
Quantification in immunocytochemistry is notoriously
difficult and it was for this reason that we chose a relatively
straightforward method of assessment of staining in this
study, i.e. whether a given cell was positive or negative.
Precise measurement of antigen levels cannot be achieved
currently by immunocytochemical methods. Our work
however, does indicate that the amount of NCRC 11 antigen
present may be a valuable prognostic indicator in breast
cancer. Other more sensitive methods of measurement of
antigen levels such as radioimmunoassay, flow cytometry or
enzyme linked immunosorbent-assay may allow more
accurate measurement of NCRC 11 antigen in tumours.
The results of other groups using similar antibodies have
been conflicting. Wilkinson et al. (1984), using HMFGI and
HMFG2, reported a significant association between extra
cellular staining with HMFGI and good survival in patients
with breast cancer. Other groups, using HMFGI and
HMFG2 (Berry et al., 1985), and Mam 3 antibodies
(Rasmussen et al., 1985), also raised to HMFGM have not
confirmed these results. The glycoprotein antigen Mam 6,
present on the HMFGM has been shown to be elevated in
the serum of patients with breast carcinoma, particularly
those patients with tumours of an advanced stage (Hilkens et
al., 1986). The epitope identified by one antibody to this
antigen, 115D8, although not the epitope identified by
NCRC 11, is present on the NCRC 11 antigen (Price et al.,
1986). Work with NCRC 11 is in progress in other labora-
tories. Preliminary results from one group (Angus et al.,
1986) have shown that patients whose tumours had a low
number of cells staining positively had a poorer prognosis,
but this did not attain statistical significance. However the
follow up period in the study was short, with a minimum of
30 months.
The assessment of immunohistological staining with
NCRC 11 used in this study is a relatively simple semiquanti-
tative method. It does not account for the many different
patterns and variable distribution of the NCRC 11 antigen
seen in breast carcinomas, from purely luminal surface
staining (Figure IA) to diffuse intracytoplasmic staining
(Figure IB). Analysis of these patterns may show relation-
ships to histological tumour type or give information about
the relationships to histological grade and may improve the
understanding of the diverse morphological patterns of
human breast cancer.
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